Virbez 300 Adverse Reactions

In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the Irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for Irbesartan treated patients (3.3%) than for placebo treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment. In diabetic hypertensive patients with micro albuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.
The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received Irbesartan. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in > 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.
The frequency of adverse reactions listed as follows is defined using the following convention: Very common (≥ 1/10); common (≥ 1/100, < 1/10); Uncommon (≥ 1/1000, < 1/100); Rare (≥ 1/10,000, < 1/1,000); Very rare (< 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Adverse reactions additionally reported from post marketing experience are also listed. These adverse reactions are derived from spontaneous reports. (See table.)

Click on icon to see table/diagram/image

Paediatric population: In a randomized trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%); hypotension (2.2%); dizziness (1.9%); cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.